Glucagon Hyperglycemia: A Checklist Guide to Peptide Product Composition
Abstract: Glucagon-induced hyperglycemia management relies on precise peptide product composition. This checklist evaluates key parameters: purity (>98%), stability (lyophilized vs. liquid), and excipient profiles (e.g., trehalose, polysorbate). Market trends show a 12.3% CAGR (2024–2030) driven by diabetes and hypoglycemia therapeutics. Brand comparison highlights Novo Nordisk’s FDA-approved GlucaGen® vs. generic alternatives with varying bioactivity. Technical advantages include rapid onset (5–15 min) and reversible action; drawbacks include short shelf-life (24–36 months) and cold-chain logistics (2–8°C). Product certifications (GMP, USP <797>) ensure quality. Selection criteria prioritize purity, reconstitution ease, and regulatory compliance. Industry data indicates 78% of brands lack third-party purity testing, underscoring due diligence.